HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Columbia Labs

This article was originally published in The Tan Sheet

Executive Summary

Approximately 50-65 sales reps to be hired within next six months to detail vaginal pH reducer Miphil, Advantage-S spermicide to OB/GYNS. OTC products will be renamed, repositioned to professional audiences, firm says during analysts' call Aug. 9. Columbia hopes to finalize agreement "with a consumer products company which will assist in marketing these products in the OTC arena" within next few months. Q2 net revenues fell 84% to $427,554, with firm attributing decrease partly to "absence of revenues" from OTC brands sold to Lil' Drugstore Products last year (1"The Tan Sheet" April 24, 2000, In Brief)

You may also be interested in...

Columbia Labs

Company moves forward in its attempt to shed its OTC marketing presence by signing an agreement with Lil' Drugstore Products. Under the deal, Lil' Drugstore is purchasing the Replens and Diasorb brands and acquiring the U.S. licensing and trademark rights to Legatrin and Vaporizer in a Bottle for "$4.5 mil. plus existing inventory on closing, a royalty stream in excess of $1 mil. annually," Columbia announces April 20. Lil' Drugstore will have the option to buy full rights to the latter two brands for "several million dollars." Proceeds from the sales will be used to focus on Columbia's Rx offerings. The firm is retaining the OTC Advantage-S spermicide as well as its vaginal pH reducer Miphil

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts